

28th October 2023

To,

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001 THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East) Mumbai - 400051

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received a Notice from Kerala State GST authorities, seeking to disallow transitional Excise duty credit (TRAN 1 credit) claimed in Kerala State. The relevant details to be is disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	State Tax Officer, State Goods and
		Services Tax Department
		Tax Payer Services Circle, Vyttila,
		Tripunithura- 682301
2	Nature and details of the action(s) taken, initiated or order(s)	Disallowance of TRAN 1 credit taken
	passed	by the Company in Kerala State
3	Date of receipt of direction or order, including any ad-interim or	27 th October 2023
	interim orders, or any other communication from the authority	
4	Details of violation(s) / contravention(s) committed or alleged	Disallowance of TRAN 1 credit taken
	to be committed	by the Company in Kerala State
5	Impact on financial, operation or other activities of the listed	Tax & interest Rs.8,05,330/-; Penalty
	entity, quantifiable in monetary terms to the extent possible	Rs.40,635/-

Since this issue in procedural in nature, the Company is settling the issue basis internal assessment. There is a penalty of Rs.40,635/- which is also procedural in nature under Section 73 of GST Act and not specific to any suppression, willful misstatement done by the Company.

Kindly take the same on the record.

Thanking you,

Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary

CIN: L24239MH1924PLC001151